Senior Vice-President, Alliance Management, Galapagos, Mechelen (Belgium
Dr. Gerben van ‘t Klooster studied pharmacy, and holds a PhD in pharmacology (Utrecht).
Gerben has been active in the pharma-biotech industry for over 25 years. He led development programs in virology, gastro-intestinal and inflammatory diseases, from preclinical through all clinical phases and registration, six of which delivered marketed drugs.
Gerben joined Galapagos in 2009 to lead its emerging drug development programs, including filgotinib, now filed for registration. He was overall responsible for Galapagos’ early drug development portfolio until he was appointed Head of Alliance Management end of 2019, following the transformational agreement with US-based Gilead